SE412906B - Forfarande for framstellning av 3-aryloxi-3-fenylpropylaminer med farmakologisk verkan - Google Patents

Forfarande for framstellning av 3-aryloxi-3-fenylpropylaminer med farmakologisk verkan

Info

Publication number
SE412906B
SE412906B SE7500215A SE7500215A SE412906B SE 412906 B SE412906 B SE 412906B SE 7500215 A SE7500215 A SE 7500215A SE 7500215 A SE7500215 A SE 7500215A SE 412906 B SE412906 B SE 412906B
Authority
SE
Sweden
Prior art keywords
propylamines
aryloxy
phenyl
procedure
preparation
Prior art date
Application number
SE7500215A
Other languages
English (en)
Swedish (sv)
Other versions
SE7500215L (de
Inventor
B B Molloy
K K Schmiegel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26625843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE412906(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority claimed from KR1019750000261A external-priority patent/KR800001009B1/ko
Publication of SE7500215L publication Critical patent/SE7500215L/xx
Publication of SE412906B publication Critical patent/SE412906B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE7500215A 1974-01-10 1975-01-09 Forfarande for framstellning av 3-aryloxi-3-fenylpropylaminer med farmakologisk verkan SE412906B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US05/432,379 US4314081A (en) 1974-01-10 1974-01-10 Arloxyphenylpropylamines
KR1019750000261A KR800001009B1 (ko) 1975-01-09 1975-01-09 아릴옥시페닐프로필 아민류의 제조방법

Publications (2)

Publication Number Publication Date
SE7500215L SE7500215L (de) 1975-07-11
SE412906B true SE412906B (sv) 1980-03-24

Family

ID=26625843

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7500215A SE412906B (sv) 1974-01-10 1975-01-09 Forfarande for framstellning av 3-aryloxi-3-fenylpropylaminer med farmakologisk verkan

Country Status (23)

Country Link
US (1) US4314081A (de)
JP (1) JPS5939418B2 (de)
AR (3) AR205578A1 (de)
AT (1) AT336000B (de)
BE (1) BE824255A (de)
BG (3) BG26192A3 (de)
CA (1) CA1051034A (de)
CH (1) CH609675A5 (de)
CS (1) CS189680B2 (de)
DD (1) DD118613A5 (de)
DE (1) DE2500110A1 (de)
DK (1) DK140430B (de)
ES (1) ES433720A1 (de)
FR (1) FR2257288B1 (de)
GB (1) GB1493961A (de)
IE (1) IE40346B1 (de)
NL (2) NL181654C (de)
PH (1) PH11652A (de)
RO (2) RO70660A (de)
SE (1) SE412906B (de)
SU (1) SU1005655A3 (de)
YU (3) YU36915B (de)
ZA (1) ZA7532B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK156565B (da) * 1978-01-20 1989-09-11 Erba Carlo Spa Analogifremgangsmaade til fremstilling af substituerede morpholinderivater

Families Citing this family (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584404A (en) * 1974-01-10 1986-04-22 Eli Lilly And Company Substituted phenoxyphenylproply dimethylamines
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
JPS5283811A (en) * 1976-01-01 1977-07-13 Lilly Co Eli Aryloxy phenyl propylamines and their salts
GB1570613A (en) * 1976-10-27 1980-07-02 Akzo Nv Biologically active tricyclic compounds and pharmaceutical compositions containing same
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
FR2455571A2 (fr) * 1979-02-15 1980-11-28 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre medicaments
DE3017812A1 (de) * 1980-05-09 1981-11-12 Merck Patent Gmbh, 6100 Darmstadt Cyclopropanderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US4430319A (en) 1982-05-21 1984-02-07 State University Of New York Radioactive iodine labeled phenolic amines
US4824868A (en) * 1982-09-07 1989-04-25 Ciba-Geigy Corporation Propylamine derivatives useful for the treatment of dementia
US4692469A (en) * 1982-09-07 1987-09-08 Ciba-Geigy Corporation Propylamine derivatives
US4590213A (en) * 1983-04-08 1986-05-20 Eli Lilly And Company Anti-anxiety method
HU207282B (en) * 1984-05-31 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
US4683235A (en) * 1985-02-25 1987-07-28 Eli Lilly And Company Analgesic method
US4594358A (en) * 1985-02-25 1986-06-10 Eli Lilly And Company Analgesic method
US4777291A (en) * 1985-02-27 1988-10-11 Eli Lilly And Company Racemization process
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
US5149714A (en) * 1987-08-14 1992-09-22 Merrell Dow Pharmaceuticals Inc. Antidepressants
US5223540A (en) * 1987-10-22 1993-06-29 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
US4971998A (en) * 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
US4876282A (en) * 1987-11-25 1989-10-24 Eli Lilly And Company 1-Phenylalkylamines as selective serotonin uptake inhibitors
US4996235A (en) * 1987-11-25 1991-02-26 Eli Lilly And Company 3,4-diphenylbutanamines
US5238959A (en) * 1988-04-08 1993-08-24 Eli Lilly And Company 3-phenyloxy-3-phenyl propanamines
ZA892517B (en) * 1988-04-08 1990-12-28 Lilly Co Eli Propanamine derivatives
US5250571A (en) * 1988-11-14 1993-10-05 Eli Lilly And Company (S)-norfluoxetine in method of inhibiting serotonin uptake
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
IT1228209B (it) * 1989-01-10 1991-06-05 Grato Magnone Procedimento per la preparazione di fluoxetina cloridrato.
FI81083C (fi) * 1989-03-03 1990-09-10 Orion Yhtymae Oy Ett foerbaettrat foerfarande foer framstaellning av n-metyl-3-(p-trifluormetylfenoxi)-3-fenylpropylamin hydroklorid.
US5166437A (en) * 1989-03-03 1992-11-24 Orion-Yhtyma Oy Process for the preparation of fluoxetine
DK258389D0 (da) * 1989-05-26 1989-05-26 Ferrosan As Aryloxyphenylpropylaminer, deres fremstilling og anvendelse
JPH0375680U (de) * 1989-11-21 1991-07-30
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5250572A (en) * 1990-03-29 1993-10-05 Eli Lilly And Company (R)-norfluoxetine in method for occupying serotonin IC receptors
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
PH30083A (en) * 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
US5136078A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Synthesis of b-cyanohydrins
US5136079A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Regioselective synthesis
US5320825A (en) * 1991-05-01 1994-06-14 Trustees Of The University Of Pennsylvania Serotonin reuptake inhibitors for S.P.E.C.T. imaging
WO1993000811A1 (en) * 1991-07-01 1993-01-21 The General Hospital Corporation Invertebrate phenylethanolamine transporter and the use thereof
IL99316A (en) 1991-08-27 1995-03-15 Teva Pharma Production of fluoxetine and new intermediates
US5202319A (en) * 1991-09-23 1993-04-13 Hoechst-Roussel Pharmaceuticals Inc. Substituted 3-amino-2,3,4,5-tetrahydro-1-aryloxy-3-benzazepines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
EP0537915B1 (de) * 1991-09-27 1995-07-12 Eli Lilly And Company N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)Propylamine als Norepinephrineinhibitoren
HU9202128D0 (en) * 1992-06-26 1992-10-28 Richter Gedeon Vegyeszet Method for producing n-methyl-(3-phenyl-3-(4-[trifluoro-methyl])-phenooxi-)-amine
EP0576766A1 (de) * 1992-06-29 1994-01-05 Novo Nordisk A/S Propanolamin-Derivate, ihre Herstellung und Verwendung
US7087765B2 (en) * 1995-06-07 2006-08-08 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6017965A (en) * 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
EP0714663A3 (de) 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
ES2101650B1 (es) * 1995-06-29 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfenoxi) propilamina.
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
ES2101654B1 (es) * 1995-07-24 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
ES2101655B1 (es) * 1995-07-28 1998-01-16 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3-(p-trifluorometilfe noxi) propilamina.
ES2103680B1 (es) * 1995-08-03 1998-04-01 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil-3- (p-trifluorometilfenoxi)propilamina.
WO1997006792A1 (en) * 1995-08-16 1997-02-27 Eli Lilly And Company Potentiation of serotonin response
ES2103681B1 (es) * 1995-09-19 1998-04-01 Lilly Sa Procedimiento de preparacion de n-metil-3-fenil - (p-trifluorometilfenoxi) propilamina.
IT1283141B1 (it) * 1996-07-11 1998-04-07 Laporte Organics Francis S P A Procedimento per la preparazione di n-metil-3-(p-trifluorometilfenossi)-3-fenilpropilamina e dei suoi
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5830500A (en) * 1996-07-22 1998-11-03 Pentech Pharmaceuticals, Inc. Low dose fluoxetine tablet
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US6303595B1 (en) * 1997-11-14 2001-10-16 Akzo Nobel N.V. Use of mirtazapine for treating sleep apneas
US5936124A (en) * 1998-06-22 1999-08-10 Sepacor Inc. Fluoxetine process from benzoylpropionic acid
US6025517A (en) * 1998-08-03 2000-02-15 Sepracor Inc. Fluoxetine process from benzoylacetonitrile
AU2180400A (en) * 1999-01-13 2000-08-01 Eli Lilly And Company A pharmaceutical combination for the treatment of depression
FR2791345B1 (fr) * 1999-03-26 2001-05-04 Adir Nouveaux derives du benzo[3,4]cyclobuta[1,2-c]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2000058262A1 (en) * 1999-03-29 2000-10-05 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
PL211402B1 (pl) * 1999-09-03 2012-05-31 Apbi Holdings Zastosowanie dapoksetyny do leczenia lub zwalczania przedwczesnej ejakulacji
WO2001044166A1 (en) 1999-12-17 2001-06-21 Ranbaxy Laboratories Limited Process for the preparation of fluoxetine hydrochloride
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004152D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004149D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
US6273260B1 (en) 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
EP1284729A4 (de) * 2000-04-13 2007-12-19 Mayo Foundation A-(beta)-42 senkende arzneimittel
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6310250B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form A of fluoxetine hydrochloride
US6310251B1 (en) 2001-01-31 2001-10-30 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6258853B1 (en) 2001-01-31 2001-07-10 Grayson Walker Stowell Form a of fluoxetine hydrochloride
US6313350B1 (en) 2001-01-31 2001-11-06 Grayson Walker Stowell Form a of fluoxetine hydrochloride
ATE396170T1 (de) 2001-03-06 2008-06-15 Lilly Co Eli Monoamin-aufnahme-inhibitor
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
AR035700A1 (es) * 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
MXPA04000979A (es) * 2001-07-31 2005-02-17 Upjohn Co Tratamiento de dolor cronico con 3-ariloxi-3-fenilpropanaminas.
SE0102641D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
US20040170688A1 (en) * 2001-08-06 2004-09-02 Deshmukh Abhijit Mukund Enteric formulation of fluoxetin
CA2457385A1 (en) 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
US6630454B2 (en) 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
US7119083B2 (en) * 2001-10-12 2006-10-10 Azevan Pharmaceuticals, Inc. β-Lactamyl vasopressin V1a Antagonists
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
WO2003047560A1 (en) * 2001-11-30 2003-06-12 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
AU2002352625A1 (en) * 2001-12-11 2003-06-23 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
EP2316468A1 (de) 2002-02-22 2011-05-04 Shire LLC Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Dextroamphetamin
AU2003273281A1 (en) * 2002-05-31 2003-12-19 The Forsyth Institute Methods for increasing bone density
JP2004077714A (ja) * 2002-08-15 2004-03-11 Fuji Xerox Co Ltd 光走査装置
SE0203304D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
US6846957B2 (en) * 2002-11-22 2005-01-25 Board Of Regents, The University Of Texas System Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
JP2006523674A (ja) * 2003-04-18 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 慢性閉塞性肺疾患（ｃｏｐｄ）のための組合せ治療法
SG141430A1 (en) * 2003-05-30 2008-04-28 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as hmg-co inhibitors
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
US20060100290A1 (en) * 2003-07-28 2006-05-11 Dunaway Leslie J Treatment of allergic rhinitis and asthma
KR100828218B1 (ko) 2003-09-12 2008-05-07 화이자 인코포레이티드 알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물
DK1668014T3 (da) * 2003-09-17 2009-04-20 Janssen Pharmaceutica Nv Kondenserede heterocykliske forbindelser som serotoninreceptormodulatorer
WO2005051919A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
EP1715856B1 (de) * 2003-12-31 2012-07-11 Actavis Group PTC ehf. Atomoxetin-formulierungen
EP1732610A2 (de) * 2004-03-26 2006-12-20 Baylor University Gezielte inhibitoren der serotonin-wiederaufname
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
US20050233010A1 (en) * 2004-04-19 2005-10-20 Satow Philip M Lithium combinations, and uses related thereto
US20050252144A1 (en) * 2004-04-29 2005-11-17 Macdonald Robert A Veneers for walls, retaining walls and the like
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006037055A1 (en) * 2004-09-27 2006-04-06 Dr. Reddy's Laboratories Ltd. Synthesis of atomoxetine hydrochloride
JP2007523213A (ja) * 2004-12-23 2007-08-16 テバ ファーマシューティカル インダストリーズ リミティド 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
EP1856087A1 (de) * 2005-03-08 2007-11-21 Teva Pharmaceutical Industries Limited Kristallformen von (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamin-oxalat und deren herstellung
MX2007011254A (es) * 2005-03-14 2007-10-18 Teva Pharma Proceso para la preparacion de (s)-(+)-n,n-dimetil-3-(1- naftaleniloxi)-3-(2-tienil)propanamina opticamente activa.
CA2601709C (en) 2005-03-22 2017-02-14 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids
AR056980A1 (es) 2005-04-22 2007-11-07 Wyeth Corp Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
BRPI0610037A2 (pt) * 2005-04-22 2010-05-25 Wyeth Corp derivados de dihidrobenzofurano e uso dos mesmos
EP1879875A1 (de) * 2005-04-22 2008-01-23 Wyeth Kristallformen von {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amin-hydrochlorid
JP2008538573A (ja) 2005-04-22 2008-10-30 ワイス ベンゾフラニルアルカナミン誘導体およびその５−ｈｔ２ｃアゴニストとしての使用
JP2008539047A (ja) 2005-04-28 2008-11-13 プロテウス バイオメディカル インコーポレイテッド ファーマインフォーマティックスシステム
NZ565683A (en) * 2005-07-08 2011-04-29 Braincells Inc Methods for identifying agents and conditions that modulate neurogenesis in human neural cells
US7485754B2 (en) * 2005-07-08 2009-02-03 Apotex Pharmachem Inc. Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
CN101268068B (zh) 2005-07-19 2015-12-02 阿泽范药品公司 β-内酰胺基苯丙氨酸、半胱氨酸和丝氨酸血管加压素拮抗剂
AU2006272760A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
US7842717B2 (en) * 2005-09-22 2010-11-30 Teva Pharmaceutical Industries Ltd. DNT-maleate and methods of preparation thereof
US20080207923A1 (en) * 2005-09-22 2008-08-28 Santiago Ini Pure DNT-maleate and methods of preparation thereof
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (de) 2005-10-31 2008-07-16 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
CN1304360C (zh) * 2005-12-12 2007-03-14 天津大学 N,n－二甲基－3－羟基－3－芳基丙胺的制备方法
EP1844034A1 (de) * 2006-01-23 2007-10-17 Teva Pharmaceutical Industries Ltd Dnt-fumarat, und verfahren zu dessem herstellung
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
TW200744583A (en) * 2006-03-14 2007-12-16 Ranbaxy Lab Ltd Statin stabilizing dosage formulations
KR20080105104A (ko) * 2006-03-24 2008-12-03 와이어쓰 우울증 치료를 위한 신규한 치료학적 병용제
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) * 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20080027128A1 (en) * 2006-05-23 2008-01-31 Santiago Ini Duloxetine HCL polymorphs
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
US20080153896A1 (en) * 2006-07-14 2008-06-26 Gyan Chand Yadav Polymorphic Forms of an HMG-CoA Reductase Inhibitor and Uses Thereof
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
WO2008026227A2 (en) * 2006-08-28 2008-03-06 Matrix Laboratories Ltd A process for the preparation of atomoxetine hydrochloride
JP2010502722A (ja) * 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2663347A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
ITMI20061987A1 (it) 2006-10-16 2008-04-17 Archimica Srl Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine.
WO2008062473A1 (en) * 2006-10-31 2008-05-29 Cadila Healthcare Limited Process for preparing atomoxetine hydrochloride
FR2910319B1 (fr) 2006-12-20 2011-06-03 Substipharm Dev Formulations pharmaceutiques dispersibles contenant de la fluoxetine
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
EP2125017A2 (de) * 2007-01-11 2009-12-02 Braincells, Inc. Neurogenese-modulation durch verwendung von modafinil
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
US20090137598A1 (en) 2007-06-21 2009-05-28 Veroscience, Llc Method of treating metabolic disorders and depression with dopamine receptor agonists
WO2009141833A2 (en) * 2008-04-17 2009-11-26 Ind-Swift Laboratories Limited An improved process for synthesizing highly pure atomoxetine
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
WO2011027359A2 (en) 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
EP2348120B1 (de) 2009-12-30 2014-06-11 Universität Wien Enzymatische Reduktion von 1-Phenylpropanon und Derivate davon
ES2858499T3 (es) 2010-07-01 2021-09-30 Azevan Pharmaceuticals Inc Compuestos para su uso en el tratamiento de trastorno explosivo intermitente
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
KR20140045925A (ko) 2011-03-17 2014-04-17 루핀 리미티드 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
EP2879517A1 (de) 2012-07-31 2015-06-10 Sanovel Hayvan Sagligi Ürünleri Sanayi ve Ticaret A.S. Verwendung von fluoxetin zur steigerung der fleisch- und milchproduktion
WO2014021801A1 (en) 2012-07-31 2014-02-06 Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret A.S. Use of fluoxetine in animals
WO2014046544A1 (en) 2012-09-21 2014-03-27 Aapa B.V. Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators
KR20160130853A (ko) 2014-03-28 2016-11-14 아제반 파마슈티칼스, 인코퍼레이티드 신경변성 질환을 치료하기 조성물 및 방법
CN105777706B (zh) * 2014-12-25 2019-08-23 江苏恩华药业股份有限公司 一种3-[(苯并[d][1, 3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用
TW201919625A (zh) 2017-09-15 2019-06-01 美商愛治凡製藥公司 用於治療腦損傷之組合物及方法
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683742A (en) * 1951-02-23 1954-07-13 Searle & Co Nu, nu-disubstituted omega-arylmethoxy-omega-arylalkylamine derivatives
ES251290A1 (es) * 1958-08-21 1960-04-01 Parke Davis & Co Un procedimiento para la producciën de alcohilaminas arilsustituidas
US3132179A (en) * 1959-08-27 1964-05-05 Sterling Drug Inc Ethers of alpha-hydroxymethyl-beta-monocarbocyclic aryl ethyl amines and their preparation
US3253040A (en) * 1962-12-10 1966-05-24 Union Carbide Corp Process for the production of primary 3-hydrocarbyloxypropylamines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK156565B (da) * 1978-01-20 1989-09-11 Erba Carlo Spa Analogifremgangsmaade til fremstilling af substituerede morpholinderivater

Also Published As

Publication number Publication date
JPS50101333A (de) 1975-08-11
US4314081A (en) 1982-02-02
IE40346B1 (en) 1979-05-09
RO70660B (ro) 1983-08-30
DK688974A (de) 1975-09-01
GB1493961A (en) 1977-12-07
ATA10275A (de) 1976-08-15
DE2500110A1 (de) 1975-07-17
YU121581A (en) 1983-04-27
YU121481A (en) 1983-04-27
CA1051034A (en) 1979-03-20
JPS5939418B2 (ja) 1984-09-22
YU37308B (en) 1984-08-31
BG23212A3 (de) 1977-07-12
YU36915B (en) 1984-08-31
ZA7532B (en) 1976-08-25
SE7500215L (de) 1975-07-11
BG26192A3 (de) 1979-02-15
NL930108I1 (nl) 1993-10-18
DK140430B (da) 1979-08-27
YU3275A (en) 1982-06-18
FR2257288A1 (de) 1975-08-08
AR205577A1 (es) 1976-05-14
NL181654C (nl) 1987-10-01
DK140430C (de) 1980-01-21
AT336000B (de) 1977-04-12
BE824255A (fr) 1975-07-09
RO70660A (ro) 1983-09-26
DD118613A5 (de) 1976-03-12
CS189680B2 (en) 1979-04-30
NL930108I2 (nl) 1994-08-16
SU1005655A3 (ru) 1983-03-15
DE2500110C2 (de) 1987-06-11
AU7683674A (en) 1976-06-24
AR205633A1 (es) 1976-05-21
IE40346L (en) 1975-07-10
NL7500186A (nl) 1975-07-14
RO69763A (ro) 1982-02-26
PH11652A (en) 1978-05-08
CH609675A5 (de) 1979-03-15
BG60761B2 (bg) 1996-02-29
FR2257288B1 (de) 1978-07-21
ES433720A1 (es) 1976-12-01
NL181654B (nl) 1987-05-04
AR205578A1 (es) 1976-05-14
YU37307B (en) 1984-08-31

Similar Documents

Publication Publication Date Title
SE412906B (sv) Forfarande for framstellning av 3-aryloxi-3-fenylpropylaminer med farmakologisk verkan
SE424637B (sv) Analogiforfarande for framstellning av pyridylguanidiner med terapeutisk verkan
SE419605B (sv) Forfarande for framstellning av undertrycksformad gjutform
SE7513085L (sv) Forfarande for framstellning av etrar
SE405599B (sv) Forfarande for framstellning av pyridazinoner med terapeutisk verkan
BE790016A (fr) Preparation de polyphosphazenes
SE7506160L (sv) Forfarande for framstellning av n-cykloalkylmetyldekahydroisokinoline
SE409452B (sv) Forfarande for framstellning av stilbenderivat
SE415255B (sv) Forfarande for framstellning av furoylettiksyra - derivat med hypolipidemisk verkan
SE7506237L (sv) Forfarande for framstellning av dekahydroisokinolinderivat
SE425790B (sv) Forfarande for framstellning av polylaurinlactam
SE395892B (sv) Forfarande for framstellning av piperidyl-bensimidazoliner med terapeutisk verkan
SE411453B (sv) Forfarande for framstellning av 3-fluorcefalosporiner
SE403477B (sv) Forfarande for famstellning av substituerade indoleniner
SE7514308L (sv) Forfarande for framstellning av tyrosinderivat med terapeutisk verkan
SE426827B (sv) Nytt forfarande for framstellning av 7beta-acylamino-7alfa-alkoxicefalosporiner
SE7513302L (sv) Framstellning av etrar
SE7512292L (sv) Forfarande for framstellning av naftalenforeningar med terapeutisk verkan
SE7513739L (sv) Forfarande for framstellning av 2-scyl-4-oxo-pyrazino-isokonolin-derivat
SE7511801L (sv) Forfarande for framstellning av ympsampolymerisat
SE7506196L (sv) Forfarande for framstellning av amidin-hydrazon-derivat
SE388854B (sv) Forfarande for framstellning av fenylpyridylaminderivat
SE417206B (sv) Forfarande for framstellning av foreningar med autibiotisk verkan
SE389108B (sv) Forfarande for framstellning av cyklopropylfenylpyrrolidinderivat med farmakologisk verkan
SE7713839L (sv) Forfarande for framstellning av indanderivat med terapeutisk verkan

Legal Events

Date Code Title Description
SPCF Application for supplementary protection certificate filed

Free format text: 7500215

NUG Patent has lapsed

Ref document number: 7500215-4

Effective date: 19950210

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7500215-4

Format of ref document f/p: F

SPCG Supplementary protection certificate granted

Free format text: 9490183, 950905, EXPIRES: 20000109